Instituto Portugues De Reumatologia
- Address
- lock Available on a paid plan
Immune System Diseases
At Instituto Portugues De Reumatologia in Lisbon, research in rheumatology focuses strongly on immune system diseases, especially systemic lupus erythematosus and Sjögren’s syndrome. The trials are designed to assess whether new treatments can better control disease activity, improve symptoms, and support longer-term safety for people living with these chronic autoimmune conditions.
- Systemic lupus erythematosus — evaluating new therapies to reduce disease activity and improve patient outcomes
- Sjögren’s disease — testing treatments aimed at easing symptoms and strengthening disease control
- Autoimmune care — studying safety and tolerability of emerging options for long-term management
The site’s work in this area centers on improving treatment effectiveness for adults and adolescents with moderate to severe autoimmune disease.
Musculoskeletal Diseases
Clinical trials at this hospital/clinic also cover musculoskeletal diseases, with a major emphasis on psoriatic arthritis. The research is exploring new ways to relieve joint pain, reduce inflammation, and improve function, while also comparing how well different therapies work for people with active disease.
- Psoriatic arthritis — assessing treatments for joint symptoms, axial disease, and overall disease control
- Inflammatory arthritis — evaluating options for patients who have not responded well to earlier therapies
- Joint and spine involvement — studying approaches that may better address axial symptoms and mobility
These studies reflect a practical focus on finding more effective and durable treatment strategies for inflammatory arthritis.
Skin and Connective Tissue Diseases
The research portfolio includes skin and connective tissue diseases, with overlap across autoimmune conditions that affect both the skin and the body’s connective tissues. Trials here are aimed at testing innovative therapies that may improve symptom control, reduce flares, and offer better long-term disease management for patients with complex inflammatory disorders.
- Connective tissue disease — studying therapies for conditions with broad systemic involvement
- Autoimmune inflammation — evaluating treatments intended to calm immune-driven disease activity
- Symptom relief — examining whether new options can improve day-to-day disease burden
Overall, the site supports research into therapies that may benefit patients whose disease affects multiple organ systems and tissues.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG5trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Instituto Portugues De Reumatologia
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis | MoonLake Immunotherapeutics AG | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ianalumab | 4 | Unknown | 2022-07-28 | 2024-05-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.